A. Fine,3 D. Cox, and B. Fontaine
|
|
- Branden Jesse Anderson
- 6 years ago
- Views:
Transcription
1 Elevation of Serum Phosphate Affects Parathyroid Hormone Levels in Only 50% of Hemodialysis Patients, Which Is Unrelated to Changes in Serum Calcium1 2 A. Fine,3 D. Cox, and B. Fontaine A. Fine, D. Cox, B. Fontaine, Section of Nephrology. St. Boniface Hospital, Winnipeg, Manitoba, Canada (J. Am. Soc. Nephrol. 1993; 3: ) ABSTRACT Hyperphosphatemia is said to cause hyperparathyroidism either by depressing the plasma levels of ionized calcium and/or by affecting serum I,25 (OH)2 vitamin D3 levels. Direct evidence that hyperphosphatemia contributes to hyperparathyroidism in hemodialysis patients is unclear because previous published data are with older parathyroid hormone (PTH) assays. Phosphate was added to the dialysate of 15 patients for 12 wk whose predialysis serum phosphates were between 1.5 and 1.9 mm (4.7 to 5.9 mg/dl) in order to further increase their serum phosphate by 0.75 mm (2.4 mg/dl) without adjustments in other medications. No patient was on vitamin D therapy. In half of the patients, PTH levels remained unchanged (nonresponders; 214 ± 64 versus 219 ± 60 ng/l), whereas in the other patients, PTH rose from 204 ± 53 to 338 ± 60 ng/l (P< 0.05; responders). The degree of induced hyperphosphatemia was virtually identical in both groups, 1.7 mm increasing to 2.4 mm. Ionized calcium was unchanged in both groups after phosphate. Plasma I,25 (OH)2 vitamin D3 levels were low to start with and remained low throughout. Nonresponders had been on dialysis twice as long as responders and had consumed over seven times more aluminum salts. Nonresponders had higher postdeferoxamine increments in plasma aluminum (3,588 ± 1,466 versus 603 ± 390; P< 0.05), although neither these amounts nor plasma levels were in the toxic range. In conclusion, ( 1) phosphate affects PTH in only 50% of hemodialysis patients; (2) these effects I Received september 2, Accepted November 25, These results were presented to the 29th Congress of the European Dialysis Transplant Association, Paris. June Correspondence to Dr. A. Fine, st. Boniface General Hospital, section of Nephroiogy, 409 Tache, Winnipeg, Manitoba. Canada, R2H 2A / /0 Journal of the American society of Nephrology Copyright C 1993 by the American Society of Nephroiogy are independent of changes in plasma levels of ionized Ca2 and I 25 (OH)2 vitamin D3; (3) the mechanism for PTH changes after this hyperphosphatemia must reside therefore in either bone or PTH glands themselves; (4) resistance to the effects of hyperphosphatemia may be related to aluminum accumulation and occurs in 50% of patients. Key Words: Hyperphosphatemia, hyperparathyroidism, 1,25 (OH,) D3 F or decades, nephrologists have attempted to rig- Idly control the serum phosphate in dialysis patients In the belief that renal bone disease, specifically hyperparathyroldism, will be ameliorated. However, direct evidence for this beneficial effect Is lacking. All descriptions and reviews of the subject ascribe a pivotal role for the hyperphosphatemla-mnduced reductions in serum ionized calcium (by precipitation) in stimulating parathyroid hormone (PTH) production (i.e., the trade-off hypothesis ) (1-4). The evidence for this phenomenon was based on early studies In which calcium phosphate deposition In tissues was widespread (5). However, this occurred In the early days of dialysis in which phosphate was poorly dialyzed, as verified by the fact that 40% of those patients had very high serum phosphates (I.e., above 2.9 mm Img/dL]) (5). Serum phosphates In more recent studies are usually 1.7 to 2.3 mm (5.2 to 7 mg/ dl), and clinical tissue calcification is now seldom, if ever, mentioned (3,4,6-8). In contrast to the tradeoff hypothesis, Increasing phosphate concentration in serum, In vitro, within the usual range found In dialysis patients, does not reduce the Ionized calcium concentration (9). Indeed In normal subjects, in vivo, a very large increase In serum phosphate (2.2 mm) Is needed to reduce total serum calcium by mm (10). If, then, calcium phosphate precipitation Is not a mechanism for phosphate-induced hyperparathyroldism, how does phosphate restriction work? There is no doubt that In early/moderate chronic renal fallure, phosphate restriction reduces PTH activity: however, this is Independent of changes in serum phosphate (1 1) and Is considered to be due to phosphate-induced Increases in 1,25 (OH)2 D3 production, leading to PTH suppression (1 2). However, this mech- Journal of the American Society of Nephrology 1947
2 Hyperphosphatemia and PTH anism is most unlikely to be effective in dialysis patients in whom blood levels of 1.25 (OH)2 D3 are invariably low (7) and, on account of renal destruction, are unlikely to be able to be stimulated. The direct evidence that phosphate reduction in dialysis patients significantly improves hyperparathyroidism is tenuous. One early and widely quoted study. purporting to demonstrate the importance of phosphate reduction, showed that PTH levels fell from 35 to 28 times normal with a reduction in serum phosphate ( 1 3); it is hard to Imagine that this confers therapeutic benefit. In another report, PTH levels did not change when the serum phosphate was brought into the normal range in dialysis patients (14). These and most other similar studies have been with older PTH assays. which often measure PTH fragments. There are no reports of the effects of phosphate on PTH values in dialysis patients with an immunoradiometric assay specific for intact hormone (which has been shown to be reliable and sensitive to changes in serum calcium concentration [15,16]). Because most of our therapeutic effort and expense in trying to lower the serum phosphate in dialysis patients is centered around those in whom the serum phosphate is between 1.5 and 2.5 mm (5 and 8 mg/ dl), we investigated whether a patient with chronic mild hyperphosphatemia would have worse hyperparathyroidism if the serum phosphate was further elevated (therebyjustifying therapeutic intervention) and whether this effect was mediated by changes in ionized calcium or 1,25 (OH)2 D3. Because changing the dosage of oral phosphate binders (calcium or aluminum) might have independent effects on PTH (17) or serum calcium, we achieved this elevation of serum phosphate by adding phosphate to the dialysate. METHODS The laboratory values of all of our hemodialysis patients (N = 60) were scrutinized. Those patients who had three consecutive monthly predialysis serum phosphates between 1.6 and 2.0 mm and who were not on vitamin D therapy were chosen for the study. Of these 1 7 patients. 1 5 gave informed consent, the study having been approved by the university and the hospital ethics committees. No changes in any phosphate-binding medication were made in the month before the study started or throughout the study. After a control period of 3 to 4 wk in which weekly biochemical determinations were made, sodium phosphate buffer was added to the dialysis concentrate in order to give a final dialysate phosphate concentration (after dilution of the Cobe 2000 dialysis machine [Cobe, Denver, Co]) of between 1 and 2 mm. The final calcium concentration in the dialysate was not affected by this addition of phosphate. Phosphate was added to the dialysate to increase the predlalysis serum phosphate by approximately 0.75 mm (2.4 mg/dl). Predlalysis serum phosphates were determined at each dialysis until the desired increment was produced. and was usually obtained within 3 wk. Weekly serum phosphates were then obtained over the next 1 0 to 1 2 wk, with minor adjustments in the amount of phosphate added to maintain steady blood levels. In almost all patients. no adjustments were needed over the last 7 wk of the study. Within 6 wk from the end of this study period, predeferoxamine (DFO) and post-dfo infusion serum aluminum levels were determined. DFO was Infused at 40 mg/kg over 2 h at the end of a dialysis. with predlalysis serum aluminum repeated at the next dialysis. Aluminum medications were discontinued during the test. The results given in the text are from the following determinations: pre-serum phosphate is the mean of three weekly predialysis values obtained before phosphate was added to the dialysate, and post-phosphate addition phosphate is the mean of three predialysis phosphate values at weekly intervals during 1 0 to 1 2 wk of phosphate addition. PTH values are the mean of two values obtained 1 to 3 wk before phosphate addition and similarly at weeks 1 0 and 12 (postphosphate addition values). Ionized calcium values were taken at exactly the same time as the serum phosphates described above. Plasma 1,25 (OH)2 D3 and aluminum levels were taken 1 wk before phosphate addition and at the 1 2th week (one determination for each period). Serum phosphate. creatinine, and alkaline phosphatase were determined by autoanalyzer, and ionized calcium was determined by Ion-specific electrode (Ciba-Corning Co., Ontario, Canada). Intact PTH hormone and 1,25 (OH)2 D3 were measured by RIA (Nichols Institute, San Juan Capistrano. CA), and serum aluminum was measured by atomic absorption spectrophotometry. The normal values for Ca2, PTH, 1.25 (OH2) D3, and aluminum levels are to 1.32 mm, 15 to 66 ng/l, 15 to 45 pg/ml. and 0 to 222 nm, respectively. The lower limit of detection of 1.25 (OH)2 D3 is 7 pg/ml. All data are expressed as mean ± SE. STATISTICS Patients whose PTH values did not vary more than the coefficient of variation for the assay (8%) after serum phosphate elevation were classified as nonresponders. The rise in PTH in responders after phosphate was compared with baseline values by paired t test, as were the pre- and post-serum Ca2 and phosphate In both groups. For other data, responders and nonresponders are compared by use of a twotailed two-sample t test, with the exception of 1,25 (OH)2 D3 levels. Because the vast majority of patients 1948 Volume 3. Number
3 Fine et al has 1,25 (OH)2 D3 levels below normal, many of these being below the limits of accurate measurement, comparison of the proportion of patients below the normal range before and after serum phosphate dcvation was made. RESULTS Serum phosphate was raised by a mean of ± mm. In 8 of the 1 5 patients, serum PTH did not change (nonresponders), whereas In the remaining 7 patients, PTH rose by 58% (Figure 1). The smallest percent rise in PTH in this group was 38%. The baseline (prephosphate elevation) level of PTH was virtually identical in both nonresponders and responders (2 1 4 ± 64 versus 204 pm 53 ng/l, respectively). The baseline serum phosphates and their further elevations were virtually identical in both groups (Table 1). No change in serum Ca2 occurred in either group after the elevation of serum phosphate, and there was no difference in serum Ca2 values at baseline and postphosphate addition (Table 1). In an attempt to identify possible differences that could be associated with responder versus nonresponder status. various data were obtained and compared. There were no differences between age, hemoglobmn. alkaline phosphatase, and predialysis serum creatinines (Table 2). There was a marked difference in the duration of hemodialysis between the groups, nonresponders having been on dialysis more than twice as long as responders (35 ± 5.4 versus 1 6 ± 4 months; P < ). Not surprisingly, therefore, the total intake of oral aluminum was considerably higher in the nonresponders group (Table 2). However, the eightfold higher aluminum dosage was much higher than expected from the twofold increased duration of dialysis. It should be pointed out that, although these data represent a retrospective search of pharmacy records, in our unit, all drugs are issued by our own pharmacy free TABLE I. The effects on serum Ca2 and phosphate of the addition of phosphate to the dialysate Nonresponders (N=8) Responders (N=7) Phosphate (mm) 1.66 ± ± 0.1 (Pre) Phosphate (mm) 2.38 ± 0.07#{176} 2.39 ± 0.15#{176} (Post) Ca2(mM)(Pre) 1.14± ± 0.01 Ca2 (mm)(post) ± ± p< oo pre versus post. TABLE 2. Demographics and serum values in responders and nonresponders Nonresponders (N=8) Responders (N=7) Creatinine (mm) 860 ± ± 60 Aluminum (nm) 1,226 ± ± 230 Total Dose of Alumi ± ± 45#{176} num (g) (Post-Pre) DFO Alumi- 3,588 ± 1, ± 390C num (nm)b Alkaline Phosphatase 146 ± ± 15 (U/I) Hemoglobin (g/l) 89 ± ± 0.7 Duration of dialysis 35 ± ± 4#{176} (months) Age (yr) 70 ± ± 3 HCO3 (mm) 26 ± ± 1.9b 0 p< o#{149}o, nonresponders versus responders. b (Post-Pre), before and after the addition of phosphates. C p< 005, nonresponders versus responders. of charge to all of our patients and a careful record of all refills were kept so that these numbers are reasonably accurate. Serum aluminum levels tended towards higher levels in the nonresponders. but this /. p<0 05 PTH ng/i N ormal range Pie Post Pie Post Non.responders Responders Figure 1. The effects of elevating the serum phosphate on serum PTH. Individual and mean values are given before and after (Pre and Post) the addition of phosphate. Journal of the American Society of Nephrology 1949
4 Hyperphosphatemia and PTH was not statistically significant (Table 2). The rise in serum aluminum post-dfo was significantly higher in the nonresponders (3,588 ± 1,466 versus 605 ± 390 nm;p<0.05). All of the above data (Table 2) are from the prephosphate addition period with the exception of DFO infusion data, which were obtained 2 to 6 wk after the study was completed. There were no changes in mean serum bicarbonate or aluminum levels during the course of the study. With regard to 1.25 (OH)2 D3 levels, all but one patient had baseline levels below normal, the level in that patient being low normal (1 7 pg/ml). In the nonresponders. six of the seven samples (the samples from one patient were spoiled), were below normal (and three of these were below 7, which Is the lower limit of accurate assay) before the addition of phosphate. After the phosphate addition, six of the seven samples were below normal (four of these were below seven). The corresponding figures in the responder group were seven of seven below normal (four with levels below seven) before phosphate addition and seven of seven below normal (four with levels below seven) after phosphate. In other words, 1.25 (OH)2 D3 levels were far below normal and remained so throughout the study (Figure 2). PTH data were available in five of seven responders 8 to 1 2 wk after the end of the study (one patient having been transplanted. another having been transferred to another center). The PTH value fell to 23 1 ± 52 ng/l, a value no different than the control value (204 ± 53). Similarly. PTH values remained unchanged In the nonresponders at that time (228 ± 49 ng/l). DISCUSSION These results demonstrate that raising the serum phosphate in chronic hemodialysis patients has a variable effect of PTH levels, with half of the patients showing no response. Furthermore, regardless of PTH response, phosphate elevation does not reduce the serum Ionized calcium. Because serum 1,25 (OH)2 D3 levels did not change with phosphate elevation and the levels were the same In both responders and nonresponders. then the effects of phosphate on PTH in dialysis patients are not mediated via renal production of 1,25 (OH)2 D3. Our results are similar to recent findings in the dog with advanced renal failure (18). We did not measure postdialysis serum values because these are unlikely to be contributory for the following reasons: at the dialysate concentration of calcium used (1.55 mm), minimal net calcium transfer occurs so that ionized calcium levels change mmimally with small PTH changes (19); the latter is expected to be transient because of the very short (i.e., minutes) half-life of PTH. The role of phosphate elevation In the hyperparathyroidism in renal failure is unclear. The classical trade-off hypothesis (1.2) assumed that Ionized calcium levels fall after phosphate elevation, giving rise to the stimulation of PTH production. There is, however, considerable evidence against this hypothesis. Adding phosphate in vitro has little effect on Ionized calcium (9). In early renal failure, before serum phosphate rises, phosphate restriction reduces PTH production without changes in serum calcium or phosphate (1 1). NON-RESPONDERS RESPONDERS ,25 (OHL 0., pg/mi N. 15 L. L.E) PRE POST PRE POST Figure 2. Plasma 1.25 (OH)2 D3 before and after phosphate addition to the dialysate. N, lower limit of normal; l.i.d., lower limit of detection. Note that datum points below the lid. are shown for descriptive purposes but do not represent numerical values Volume 3. Number
5 Fine et al The mechanism for the reduced PTH production after phosphate restriction in early renal failure is now considered to be due to increased 1,25 (OH)2 D3 production (1 2). Renal cortical cells change from 24,25 (OH)2 D3 to 1,25 (OH)2 D3 production when phosphate concentration falls (20). 1,25 (OH)2 D3 has a significant suppressant effect on PTH production at the level of gene transcription (21). However, recent evidence in humans contradicts the above and suggests that 1,25 (OH)2 D3 production is unchanged by phosphate restriction in early renal failure (22). Furthermore, in more advanced renal failure, It is unlikely that the grossly reduced renal mass could significantly increase Its production of 1,25 (OH)2 D3 after phosphate restriction. Indeed, this has been shown In (predialysis) humans (23) and in the rat (24) with severe uremia, where 1.25 (OH)2 D3 levels remain unchanged after phosphate restriction. Our results confirm for the first time in dialysis patients the lack of a role of 1,25 (OH)2 D3 in mediating phosphate-induced changes In PTH; these levels remained low after phosphate addition without any difference in levels between those in whom PTH responded to phosphate addition and those in whom there was no such response. If, then, neither the ionized calcium nor the 1,25 (OH)2 D3 levels change, what is the mechanism for the effects of phosphate restriction on PTH production in dialysis patients, and as a corollary, what is the reason for the lack of response? Indeed, what is the evidence for phosphate-induced hyperparathyroldism In dialysis patients? Although considerable published data purport to show a beneficial effect of phosphate restriction for a variety of reasons, these data and their Interpretation are open to question. In one early report (1 3) PTH values fell with phosphate restriction but to values still 28 times normal, conferring dubious therapeutic advantage. In addition, those data were based on old (i.e ) PTH assays. Contrary evidence exists, showing no reduction in PTH levels after lowering of serum phosphate (14); the unexpected results in that study are surprising because of the additional observation that serum aluminum levels more than doubled (as phosphate was lowered by aluminum salts), aluminum being a well-known suppressant of PTH production (25). In one study. widely quoted as evidence for an effect of phosphate on PTH production, the majority of the patients studied with advanced (predialysis) renal failure had normal serum PTH values before their serum phosphates were reduced: therefore, the relevance of a fall in PTH values in that series is unclear (23). Although there are considerable data comparing various phosphate-reducing agents and vitamin D therapy on PTH production (26). because the therapy itself (e.g., aluminum, vitamin D) could have mdcpendent effects on PTH, the role of phosphate reduction Itself on PTH production has never been directly proven in dialysis patients. The above factors led to the design of our study, In which only the serum phosphate was varied and clearly only about one half of the patients showed a change in their PTH levels. Skeletal resistance to the action of PTH is probably an etiologic factor for secondary hyperparathyroid- Ism in chronic renal failure (27). Several postulated mechanisms for this include phosphate retention and changes in bone PTH receptors and bone alum!- num content. With regard to the role of phosphate retention, it has been shown in the rat that an Increase in the serum phosphate produces skeletal resistance to the calcemic action of PTH (24,28). However, In the dog, unlike the rat, PTH resistance is not restored by phosphate restriction (29). The ambient phosphate concentration in bone may be a factor in the amount of exchangeable calcium that can be mobilized by PTH, a higher phosphate leading to reduced calcium release. This has been shown in osteoclasts (30) and in the perfused rat tail preparation (31). Chronically raised PTH levels may induce down-regulation of bone receptors. leading to dimin- Ished calcemic response to PTH (32). Thus, thyroparathyroidectomy restores the calcemic effect of PTH (24,30). Our results suggest that a time factor for PTH responsiveness to hyperphosphatemia is important, but whether the above mechanisms play a role Is unclear. Whether our finding of a lower plasma bicarbonate in responders is relevant is unclear, but It has been shown that osteoclastic and osteoblastic activities are responsive to changes in ph (33). Of theoretical Interest is the possibility that free serum aluminum concentration would be decreased by a lower plasma bicarbonate, thereby reducing aluminum-induced PTH suppression. Although the described role of aluminum in renal osteodystrophy is unusually focused on the direct damage to bone by deposition of aluminum, as well as an inhibitory effect on PTH production. evidence exists for a diminished calcemic response to PTH in uremic animals loaded with aluminum (34,35). In our patients, both the duration of dialysis and the total dosage of aluminum were increased in those patients In whom PTH did not respond to the phosphate increase. It is known that stainable aluminum increases with time on dialysis (36). Unfortunately, we do not have bone morphology for these patients. However, the much greater post-dfo infusion aluminum levels In nonresponders is good evidence for greater bone accumulation in these patients. It is noteworthy that the actual levels of baseline serum aluminum as well as post-dfo Increment, although raised, are not at the levels usually assumed to represent severe body burden of aluminum (37). Our results, therefore, are strongly suggestive of a role for aluminum Journal of the American Society of Nephrology 1951
6 Hyperphosphatemia and PTH in lack of responsiveness, but further data are needed. The implications for these findings is significant; modest doses of aluminum may. after all, be reasonable therapy for the control of hyperparathyroldism. The possibility remains that PTH responsiveness Is due to subtle chronic changes within the parathyroid glands themselves that might be related to the duration of dialysis and/or to aluminum stores. Whether phosphate affects PTH itself Is controversial; evidence exists for (38) and against (39) such an effect. Whatever the signal might be is conjectural; however, it is clearly neither the circulating blood levels of ionized calcium nor 1.25 (OH)2 D3. ACKNOWLEDGMENTS This work was supported by the St. Boniface Hospital Research Foundation, Winnipeg. Canada (OH)2 D3 levels were kindly measured by M. Gratten. Royal Victoria Hospital. Montreal. REFERENCES 1. Bricker NS, Slatopoisky E, Reiss E, Avioli LV: Calcium, phosphorous and bone in renal disease and transplantation. Arch Intern Med 1969; 123: Bricker NS: On the pathogenesis of the uremic state. An exposition of the trade-off hypothe N Engl J Med 1972:286: Feinfeld DA, Sherwood LM: Parathyroid hormone and 1,25 (OH)2 D3 in chronic renal failure [Editorial Review]. Kidney Int 1988:33: Schaefer K: Uremic hyperphosphatemia-what is the therapy of choice [Editorial Review]. Nephrol Dial Transplant 1 989;4: Katz A!, Hampers CL, Mcml JP: Secondary hyperparathyroidism and renal osteodystrophy in chronic renal failure. Medicine 1969;48: Rutherford E, King 5, Perry B, et at.: Use of a new phosphate binder in chronic renal insufficiency. Kidney Int 1980;17: Shusterman NH, Wasserstein AG, Morrison G, Audet P. Fallon MD, Kaplan F: Controlled study of renal osteodystrophy in patients undergoing dialysis. Am J Med 1987:82: Meric F, Yap P. Bia M: Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 1990;XVI: Adler AJ, Ferran N, Berlyne GM: Effect of inorganic phosphate on serum ionized calcium concentration in vitro: A reassessment of the trade-off hypothesis. Kidney Int 1985:28: Hebert LA, Lemann J, Petersen JR. Lennon EJ: Studies of the mechanism by which phosphate Infusion lowers serum calcium concentration. J Clin Invest 1966:45: Slatopoisky E, Caglar 5, Gradowska L, Canterbury JM, Reiss E, Bricker NS: On the prevention of secondary hyperparathyroidism in exper!- mental chronic renal disease using proportional reduction of dietary phosphorous intake. Kidney Int 1972:2: Portale AA, Halloran BP, Morris RC Jr: Physiological regulation of the serum concentration of 1,25-dihydroxy vitamin D by phosphorous in normal men. J Clin Invest 1989:83: Fournier AF, Arnaud CD, Johnson WJ, Taylor WF, Goldsmith RS: Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. J Clin Invest :50: Biswas CK, Arze RS, Ramos JM, et at.: Effect of aluminum hydroxide on serum lonised calcium,!mmunoreactive parathyroid hormone and aluminum in chronic renal failure. BMJ 1982:284: Brent GA, LeBoff MS. Seely EW, Conlin PR, Brown EM: Relationship between the concentration and rate of change of calcium and serum intact parathyroid hormone levels In normal humans. J ClIn Endocrinol Metab 1988;67: Dunlay R, Rodriguez M, Felsenfeld AJ, Liach F: Direct Inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) In dialysis patients. Kidney Int 1989:36: Kraut JA, Shinaberger JH, Singer FR, et at.: Parathyroid gland responsiveness to acute hypocalcemia in dialysis osteomalacia. Kidney Int 1983:23: Lopez-Hilker 5, Dusso AS, Rapp NS, Martin KJ, Slatopolsky E: Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1 990;259:F432-F Kaye M, Fischer D: Changes in intact parathyroid hormone levels during hemodlalysis following exposure to either differing d!alysate calcium concentrations or calcium-free dialysis with varying calcium infusion rates. Clin Nephrol 1 990;34: Tanaka Y, Deluce HF: The control of 25-hydroxyvitamin D metabolism by inorganic phosphorous. Arch Biochem Blophys 1 973; 154: Slatopolsky E, Lopez-Hilker S. Delmez J, Dusso A, Brown A, Martin KJ: The parathyroidcalcitriol axis in health and chronic renal failure. Kidney Int 1990;38(Suppl 29):S41-S Seidel A, Stein G, Schneider 5, Schmidt-Gayk H, Ritz E: Do limited changes in phosphate intake modulate 1,25 (OH)2 D3 levels in early renal failure? Clmn Nephrol 1991:36: Lucas PA, Brown RC, Woodhead JS, Coles GA: 1,25-dihydroxycholecalciferol and parathyroid hormone In advanced chronic renal failure: Effects of simultaneous protein and phosphorous restriction. Clin Nephrol 1986:25: Rodriguez M, Martin-Malo A, Martinez ME, Torres A, Felsenfeld AJ, Liach F: Calcemic respmnse to parathyroid hormone in renal failure: Role of phosphorous and Its effect on calcitr!ol. Kidney Int 1991;40: Morrisey J, Rothstein M, Mayor G, Slatopolsky E: Suppression of parathyroid hormone secretion by aluminum. Kidney Int 1 983;23: Moriniere PR, Fournier A, Leflon A, et at.: Comparison of looh Vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperalummnemia on maintenance dialysis. Nephron 1985:39: Liach F, Massry SG, Singer FR, Kurokawa K, 1952 Volume 3. Number
7 Fine et al Kaye JM, Coburn JW: Skeletal resistance to endogenous parathyrold hormone in patients with early renal failure. A possible cause of secondary hyperparathyroidism. J Clin Endocrinol Metab 1975:41: Somerville PJ, Kaye M: Evidence that resistance to the calcemic action of parathyrold hormone in rats with acute uremia is caused by phosphate retention. Kidney Int 1979:16: Kaplan MA, Canterbury JW, Gavellas G, et at.: The calcemic and phosphaturic effects of parathyroid hormone in normal and uremic dog. Metabolism 1978:27: Yates AJ, Oreffoe ROC, Mayor K, Mundy GR: Inhibition of bone resorption by inorganic phosphate Is mediated by both reduced osteoclast formation and decreased activity of mature Osteoclasts. J Bone Miner Res 1991:6: Somerville PJ, Kayc M: Action of phosphorous on calcium release in Isolated perfused rat tail. Kidney Int 1982:22: Galcerant T, Martin K, Morrissey JJ, Slatopolsky E: Role of 1,25 dehydroxyvitammn D on the skeletal resistance to parathyroid hormone. Kidney Int 1987:32: Krieger NS, Sessler NE, Bushinsky DA: Acidosis inhibits osteoblastic and stimulates osteoclastic activity in vitro. Am J Physiol 1992; 262:F442-F Kawaguchi Y, Oda Y, Immanura N, et at. : Unresponsiveness of bone to PTH in aluminum related renal osteodystrophy. Kidney Int 1986; 29(Suppl 1 8):S49-S Lieberherr M, Grosse B, Cournot-Witmer G, Hermann-Erlee MPM, Balsan 5: Aluminum action of mouse bone cell metabolism and response to PTH and 1,25 (OH2) D3. Kidney Int 1987:31: Smith AJ, Fauger MC, Abreo K, Fanti P, Julian B, Malluche HH: Aluminum related bone disease in mild and advanced renal failure. Evidence for high prevalence and morbidity and studies on etiology and diagnosis in 1 97 patients. Am J Nephrol 1982:2: Coburn JW, Norris KC: Diagnosis of aluminumrelated bone disease and treatment of aluminum toxicity with deferoxamine. Semin Nephrol 1986;6(Suppl l): Korkor AB: Reduced binding of [3H] 1,25-dlhydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engi J Med 1987:316: Sherwood LM, Mayer GP, Ramberg CF. Kronfeld DS, Aurbach GD, Potts JT: Regulation of parathyroid hormone secretion : Proportional control by calcium, lack of effect of phosphate. Endocrinology 1 968:83: Journal of the American Society of Nephrology 1953
The Effect of Long-Term Intravenous Calcitriol Administration on Parathyroid Function in Hemodialysis
The Effect of Long-Term Intravenous Calcitriol Administration on Parathyroid Function in Hemodialysis 12 Mariano Rodriguez,3 Arnold J. Felsenfeld, Carl Williams, James A. Pederson, and Francisco Liach
More informationA calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication
Kidney International, Vol. 53 (1998), pp. 223 227 A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication JOHN E. ANTONSEN, DONALD
More informationAbnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism
Nephrol Dial Transplant (1996) 11: 1292-1298 Original Article Mephrology Dialysis Transplantation Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism. Berdud, A.
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationDisease during Chronic Hemodialysis
Etiology of Hyperparathyroidism and Bone Disease during Chronic Hemodialysis II. FACTORS AFFECTING SERUM IMMUNOREACTIVE PARATHYROID HORMONE ALBERT E. FOURNIER, CLAUDE D. ARNAUD, WILLIAM J. JOHNSON, WILLIAM
More informationDirect inhibitory effect of calcitriol on parathyroid function
Kidney International, Vol. 36 (1989), pp. 1093 1098 Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis ROBERT DUNLAY, MARIANO RODRIGUEZ, ARNOLD J. FELSENFELD,
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationShould cinacalcet be used in patients who are not on dialysis?
Should cinacalcet be used in patients who are not on dialysis? Jorge B Cannata-Andía and José Luis Fernández-Martín Affiliations: Bone and Mineral Research Unit. Hospital Universitario Central de Asturias.
More informationKobe University Repository : Kernel
Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms
More informationCalcium x phosphate product
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL
More informationDifferent effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism
Nephrol Dial Transplant (996) : 8-87 Original Article Nephrology Dialysis Transplantation Different effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe
More informationRacial differences in bone turnover rate and hyperparathyroidism in hemodialysis patients
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 1994 Racial differences in bone turnover rate and hyperparathyroidism
More informationHyperphosphatemia is associated with a
TREATMENT OPTIONS IN THE MANAGEMENT OF PHOSPHATE RETENTION * George A. Porter, MD, FACP, and Hartmut H. Malluche, MD, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality and cardiovascular
More informationHyperphosphatemia Modestly Retards Parathyroid Hormone Suppression during Calcitriol-Induced Hypercalcemia in Normal and Azotemic Rats
Original Paper Nephron 2002;92:883 888 DOI: 10.1159/000065454 Accepted: May 22, 2002 Hyperphosphatemia Modestly Retards Parathyroid Hormone Suppression during Calcitriol-Induced Hypercalcemia in Normal
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationMarie-Claude Monier-Faugere, Hanna Mawad, and Hartmut H. Malluche
Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal- Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease Marie-Claude
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationThis review examines the dynamics of parathyroid hormone
In-Depth Review Dynamics of Parathyroid Hormone Secretion in Health and Secondary Hyperparathyroidism Arnold J. Felsenfeld,* Mariano Rodríguez, and Escolástico Aguilera-Tejero *Department of Medicine,
More informationThe calcemic response to PTH in the rat: Effect of elevated PTH levels and uremia
Kidney International, Vol. 46 (1994), pp. 310 317 LABORATORY INVESTIGATION The calcemic response to PTH in the rat: Effect of elevated PTH levels and uremia J0RDI BOVER, AQUILES JARA, PEDRO TRINIDAD,1
More informationNocturnal but not Short Hours Quotidian Hemodialysis Requires an Elevated Dialysate Calcium Concentration
J Am Soc Nephrol 14: 2322 2328, 2003 Nocturnal but not Short Hours Quotidian Hemodialysis Requires an Elevated Dialysate Calcium Concentration FAYEZ AL-HEJAILI, CLAUDE KORTAS, ROSEMARY LEITCH, A. PAUL
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationGlycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy
Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant ( 1997) 12: 1223 1228 Original Article Nephrology Dialysis Transplantation Reduced calcium dialysate in CAPD patients: ecacy and limitations A. Armstrong1, J. Beer1, K. Noonan2
More informationRelative effects of PTH and dietary phosphorus on calcitriol production in normal and azotemic rats
Kidney International, T/ol. 49 (1996), pp. 1441 1446 Relative effects of PTH and dietary phosphorus on calcitriol production in normal and azotemic rats SERAFIN TALLON, ISABEL BERDUD, ALEXIS HERNANDEZ,
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More informationBsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients
Clinical Chemistry / BSMI POLYMORPHISM OF THE VITAMIN D RECEPTOR GENE Bsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients Jacopo Tagliabue, MD,1 Marco
More informationComparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):
Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients Seyed Seifollah Beladi Mousavi 1, Arman Shahriari 2 and Fatemeh Roumi 3 * 1 Department of Nephrology,
More informationMetabolic Bone Disease (Past, Present and Future Challenges in the Management)
Metabolic Bone Disease 871 151 Metabolic Bone Disease (Past, Present and Future Challenges in the Management) SNA RIZVI INTRODUCTION The past 40 years have seen some important historical events leading
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (1998) 13 [Suppl 3]: 57 61 Nephrology Dialysis Transplantation The importance of hyperphosphataemia in the severity of hyperparathyroidism and its treatment in patients with chronic
More informationBone histologic response to deferoxamine in aluminum related bone disease
Kidney International, Vol. 31 (1987), pp. 1344 135 CLINICAL INVESTIGATION Bone histologic response to deferoxamine in aluminum related bone disease DENNIS L. ANDRESS, HENRY G. NEBEKER, SUSAN M. OTT, DAVID
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationKey words: Vitamin D analogues, alfacalcidol, calcitriol, secondary hyperparathyroidism, renal dialysis
Oral cal ORAL CALCITRIOL VERSUS ORAL ALFACALCIDOL FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS RECEIVING HEMODIALYSIS: A RANDOMIZED, CROSSOVER TR IAL Samantha Moe 1, Lori D Wazny 2, Janet
More informationThe role of calcimimetics in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,
More informationNew vitamin D analogs
Kidney International, Vol. 63, Supplement 85 (2003), pp. S83 S87 New vitamin D analogs EDUARDO SLATOPOLSKY, JANE FINCH, and ALEX BROWN Renal Division, Department of Internal Medicine, Washington University
More information... . : ... PTH.
IRMA Email msarookhani@qumsacir * CRD GFR D [1,25OH 2 D 3 ] SHPT GFR» «KDOQI SHPT Ca * P P P Selectra Overt HPT = = Ca * P P > GM II DSL i IRMA ± ± ± Ca * P % % % % % % % % % % % % % % % % pgml = = > ±
More informationIntroduction/objective: Adinamic bone disease (ABD) is a common finding in peritoneal. dialysis (PD) and is associated with a
Original Article Low-calcium peritoneal dialysis solution is effective in bringing PTH levels to the range recommended by current guidelines in patients with PTH levels < 150 pg/dl Authors Thyago Proença
More informationin the treatment of peritoneal dialysis patients with renal osteodystrophy
1-α-hydroxy Hong Kong Journal vitamin of DNephrology 3 2001;3(2):74-78 ORIGINAL A R T I C L E Conversion of calcitriol to 1-α-hydroxy vitamin in the treatment of peritoneal dialysis patients with renal
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More information02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.
To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationComplications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease
Med Clin N Am 89 (2005) 549 561 Complications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease Shona Pendse, MD, Ajay K. Singh, MB, MRCP(UK)* Renal Division, Brigham and
More informationControl of Phosphate Excretion in Uremic Man
Control of Phosphate Excretion in Uremic Man E. SLATOPoLSKY, A. M. ROBSON, I. ELKAN, and N. S. BmcKER From the Renal Division, Department of Internal Medicine, Washington University School of Medicine,
More informationUPDATE ON RENAL OSTEODYSTROPHY: PATHOGENESIS AND CLINICAL MANAGEMENT
UPDATE ON RENAL OSTEODYSTROPHY: PATHOGENESIS AND CLINICAL MANAGEMENT KhashayarSakhaee,M.D. University of Texas Southwestern Medical Center at Dallas Internal Medicine Grand Rounds May 22, 1997 Name: Rank:
More informationBone Disorders in CKD
Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationPhosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer
Hemodialysis International 2015; 19:5459 Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer Toru SANAI, 1
More informationHypocalcemia 6/8/12. Normal value. Physiologic functions. Nephron a functional unit of kidney. Influencing factors in Calcium and Phosphate Balance
Normal value Hypocalcemia Serum calcium Total mg/dl Ionized mg/dl Cord blood 9.0 ~ 11.5 5.0 ~ 6.o New born (1 st 24 hrs) 9.0 ~ 10.6 4.3 ~ 5.1 24~ 48 hrs 7.0 ~12.0 4.0 ~4.7 Child 8.8 ~10.8 4.8 ~4.92 There
More informationOriginal epidemiologic studies 1 have suggested that approximately
Factors for Increased Morbidity and Mortality in Uremia: Hyperphosphatemia Nathan W. Levin, Frank A. Gotch, and Martin K. Kuhlmann Hyperphosphatemia is a metabolic abnormality present in the majority of
More informationPhosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis
IAMHD HOME HEMODIALYSIS CLINICAL PRACTICE STANDARDS AND PROCEDURES Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis PRINTED copies of Clinical Practice Standards and
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Effect on mortality of elective parathyroid surgery in one hundred and three patients with chronic kidney disease : our experience. White Rose Research Online URL for this
More informationEffect of Direction and Rate of Change of Calcium on Parathyroid Hormone Secretion in Uraemia
Nephrol Dial Transplant (1989) 4: 339-344 1989 European Dialysis and Transplant Association-European Renal Association Nephrology Dialysis Transplantation Original Article Effect of Direction and Rate
More informationFrequency of Metabolic Bone Disease in Haemodialysis Patients
Frequency of Metabolic Bone Disease in Haemodialysis Patients Pages with reference to book, From 83 To 86 Rizwan Hussain, Arshad Ahmed, Abdul Salam Soomro, Saeed Hassan Chishty, Syed Ali Jaffar Naqvi (
More informationThe hart and bone in concert
The hart and bone in concert Piotr Rozentryt III Department of Cardiology, Silesian Centre for Heart Disease, Silesian Medical University, Zabrze, Poland Disclosure Research grant, speaker`s fee, travel
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationRenal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young
Chapter 6 Renal Osteodystrophy Eric W. Young I. Introduction Renal osteodystrophy refers to bone disease that occurs in patients with kidney disease. Bone disease occurs across the full spectrum of kidney
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationOriginal Article Long term effects on mineral and bone metabolism by low versus standard calcium dialysate in peritoneal dialysis: a meta-analysis
Int J Clin Exp Med 2015;8(2):2031-2037 www.ijcem.com /ISSN:1940-5901/IJCEM0004376 Original Article Long term effects on mineral and bone metabolism by low versus standard calcium dialysate in peritoneal
More informationRenal Osteodystrophy in Pediatric Patients on Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 20, 2004 Francisco J. Cano, Marcela Valenzuela, Pedro Zambrano, Marta A. Azocar, Eduardo Wolff, Maria A. Delucchi, Eugenio E. Rodriguez Renal Osteodystrophy in Pediatric
More informationSecondary hyperparathyroidism an Update on Pathophysiology and Treatment
Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Klaus Olgaard Copenhagen Budapest Nephrology School August 2007 HPT IN CRF Renal mass Ca 2+ 1,25(OH) 2 D 3 CaR Hyperparathyroidism
More informationIndex. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition
A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation
More informationhypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause
hyperparathyroidism A 68-year-old woman with documented osteoporosis has blood tests showing elevated serum calcium and parathyroid hormone (PTH) levels: 11.2 mg/dl (8.8 10.1 mg/dl) and 88 pg/ml (10-60),
More informationNDT Advance Access published February 3, 2007
NDT Advance Access published February 3, 2007 Nephrol Dial Transplant (2007) 1 of 6 doi:10.1093/ndt/gfl840 Original Article Implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 21, 2005 Maria Mesquita, 1 Eric Wittersheim, 2 Anne Demulder, 2 Max Dratwa, 1 Pierre Bergmann 3 Bone Cytokines and Renal Osteodystrophy
More informationNew biological targets for CKD- MBD: From the KDOQI to the
New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr
More informationEarly dietary phosphorus restriction and calcium supplementation in the prevention of renal
Early dietary phosphorus restriction and calcium supplementation in the prevention of renal Giuseppe Maschio, M. D., Nicola Tessitore, M. D., A ngela D Angelo, M.D., Ermanno Bonucci, M. D., A ntonio Lupo,
More informationTO EAT OR NOT TO EAT DURING HEMODIALYSIS TREATMENT?
TO EAT OR NOT TO EAT DURING HEMODIALYSIS TREATMENT? Rana G. Rizk, PhD, MPH, LD Maastricht University, The Netherlands November, 2017 Learning objectives Review the evidence behind benefits and concerns
More informationEffect of High-flux Versus Low-flux Dialysis Membranes on Parathyroid Hormone
Dialysis Effect of High-flux Versus Low-flux Dialysis Membranes on Parathyroid Hormone Samuel H Makar, 1 Happy K Sawires, 1 Tarek M Farid, 2 Waleed M Ali, 3 Mona F Schaalan 4 1 Department of Pediatrics,
More informationRace Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients
J Am Soc Nephrol 11: 330 334, 2000 Race Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients AJAY GUPTA,* LEE R. KALLENBACH, GERARD ZASUWA,* and GEORGE W. DIVINE *Division of Nephrology
More informationDraft Labeling Package Insert Not Actual Size. BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate)
Draft Labeling Package Insert Not Actual Size BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate) DESCRIPTION: Full Size: Each opaque capsule with a white cap and white body is spin printed
More informationEffect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients
Nephrol Dial Transplant (2003) 18 [Suppl 3]: iii42 iii46 DOI: 10.1093/ndt/gfg1011 Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients Kazuhiro Shiizaki
More informationProspective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD
Kidney International, Vol. 45 (1994), pp. 1710 1721 Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD L. DARRYL QUARLES, DANIEL A. YOHAY, BARBARA A.
More informationDifferences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease
Kidney International, Vol. 64 (2003), pp. 737 742 Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease B. PETER SAWAYA, REZKALLA
More informationBone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases
Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral
More informationCKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire
Pathogenesis of Metabolic Bone Disease Stuart M. Sprague, D.O. Chief, Division of Nephrology and Hypertension Professor of Medicine NorthShore University HealthSystem University of Chicago Pritzker School
More informationTreatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)
Kidney International, Vol. 65 (2004), pp. 1914 1926 Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study) WAJEH Y. QUNIBI,ROBERT E. HOOTKINS,LAVETA
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationK/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients
http://www.kidney-international.org & 2008 International Society of Nephrology original article see commentary on page 674 K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease
More informationCorporate Presentation January 2013
Corporate Presentation January 2013 0 Forward-Looking Statements Certain statements and information included in this presentation are forwardlooking statements under the Private Securities Litigation Reform
More informationInpatient Pediatric Endocrinology. Tala Dajani MD MPH Pediatric Endocrinology of Phoenix
Inpatient Pediatric Endocrinology Tala Dajani MD MPH Pediatric Endocrinology of Phoenix Objectives Identify calcium disorders in the hospital Distinguish between temporary versus permanent glucose problems
More informationFactors Affecting Calcium Metabolism in Disorders of the Kidney*
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 11, No. 4 Copyright 1981, Institute for Clinical Science, Inc. Factors Affecting Calcium Metabolism in Disorders of the Kidney* MURRAY J. FAVUS, M.D. Departm
More informationGuidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism
Nephrol Dial Transplant (16) 11 [Suppl 3]: 6-101 Nephrology Dialysis Transplantation Guidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism E. Fernandez 1 and F.
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationNew aspects of acid-base disorders
New aspects of acid-base disorders I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Division of Nephrology, Hypertension and Transplantation University of Florida College of Medicine
More informationImprovement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 24, 2008 Matthew J. Novak, 1 Heena Sheth, 2 Filitsa H. Bender, 1 Linda Fried, 1,3 Beth Piraino 1 Improvement in Pittsburgh Symptom Score Index After Initiation of
More informationEtiology of Hyperparathyroidism and Bone Disease during Chronic Hemodialysis
Etiology of Hyperparathyroidism and Bone Disease during Chronic Hemodialysis I. ASSOCIATION OF BONE DISEASE WITH POTENTIALLY ETIOLOGIC FACTORS ALBERT E. FouRIN=m, WaILLAM J. JOHNSON, DONALD R. TAVES, JOHN
More informationRamzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016
Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD
More informationConsiderations for the Treatment of Secondary Hyperparathyroidism in Renal Failure
DISEASEOF THE MONTH Considerations for the Treatment of Secondary Hyperparathyroidism in Renal Failure ARNOLD J. FELSENFELD Department of Medicine, West Los Angeles Veterans Affairs Medical Center, and
More informationOutline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010
Outline The Role of Vitamin D in CKD Priscilla How, Pharm.D., BCPS Assistant Professor National University of Singapore Principal Clinical Pharmacist National University Hospital (Pharmacy and Nephrology,
More informationThe Calcimimetic Agent AMG 073 Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary Hyperparathyroidism
J Am Soc Nephrol 13: 1017 1024, 2002 The Calcimimetic Agent AMG 073 Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary Hyperparathyroidism WILLIAM G. GOODMAN,* GERALD A. HLADIK,
More information